ADVENTRX Announces Positive CoFactor Study Data at AACR Special Conference in Cancer Research
October 21 2005 - 8:30AM
Business Wire
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that
positive preclinical data from a study with CoFactor(TM) in a
colorectal cancer model were presented at the American Association
for Cancer Research (AACR) special conference in cancer research,
Colorectal Cancer: Molecular Pathways and Therapies. The study
suggests that CoFactor in combination with 5-fluorouracil (5-FU)
and oxaliplatin may be an effective chemotherapeutic regimen
against colorectal cancer, with higher efficacy and lower toxicity
than the equivalent 5-FU, oxaliplatin and leucovorin regimen.
ADVENTRX's director of preclinical programs, Mark J. Cantwell,
Ph.D., and chief technical officer, Joan M. Robbins, Ph.D.,
coauthored the study titled, "5,10-Methylenetetrahydrofolate
Enhances Antitumor Activity and Reduces Toxicity of 5-Fluorouracil
Plus Oxaliplatin Combination Therapy in a Colorectal Cancer
Xenograph Model." The poster, presented by Dr. Cantwell in poster
session A on October 20 from 5:30-7:30pm, is available via the
Company's Web site at www.adventrx.com. The conference is being
held from October 19-23 at the Laguna Cliffs Marriott Resort and
Spa in Dana Point, Calif. "While combination therapy with 5-FU,
leucovorin and oxaliplatin has shown improved clinical efficacy in
treating colorectal cancer compared with 5-FU and leucovorin,
optimum efficacy with oxaliplatin combination therapy might not be
achieved in this combination due to multiple factors. Among these
are oxaliplatin's well characterized toxicity and that leucovorin
may contribute to the severity of 5-FU's systemic toxicity," said
Dr. Cantwell. "Preclinical data suggest that CoFactor as a
replacement for leucovorin may result in improved overall efficacy
and lower toxicity of 5-FU-containing regimens. CoFactor has
already demonstrated antitumor activity with an apparent safer
toxicity profile in combination with 5-FU in Phase I and Phase II
clinical trials in treatment of metastatic colorectal cancer."
About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on introducing new
technologies for anticancer and antiviral treatments that improve
the performance and safety of existing drugs, by addressing
significant problems such as drug metabolism, toxicity,
bioavailability and resistance. The Company's lead compound,
CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely
used cancer chemotherapy. CoFactor is currently being tested with
5-FU in a US-based Phase II and an EU-based Phase IIb clinical
trial as a first line treatment of metastatic colorectal cancer. In
addition, CoFactor has received clearance under a special protocol
assessment from the FDA to begin a Phase III pivotal clinical trial
for metastatic colorectal cancer. More information can be found on
the Company's Web site at www.adventrx.com. Forward-Looking
Statement This press release contains forward-looking statements
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the US Food and Drug Administration and other
regulatory agencies. For a discussion of such risks and
uncertainties, which could cause actual results to differ from
those contained in the forward-looking statements, see "Risk
Factors" in the Company's last quarterly report on Form 10-Q, as
well as other reports that the Company files from time to time with
the Securities and Exchange Commission. All forward-looking
statements are qualified in their entirety by this cautionary
statement. The Company undertakes no obligation to release publicly
any revisions, which may be made to reflect events or circumstances
after the date hereof.
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024